Cargando…
Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer via caspase-1 activation
Cytochrome P450 1B1 (CYP1B1) is recognized as a universal tumor biomarker and a feasible therapeutic target due to its specific overexpression in cancer tissues. Despite its up-regulation in prostate cancer (PCa), biological significance and clinicopathological features of CYP1B1 are still elusive....
Autores principales: | Chang, Inik, Mitsui, Yozo, Kim, Seul Ki, Sun, Ji Su, Jeon, Hye Sook, Kang, Jung Yun, Kang, Nam Ju, Fukuhara, Shinichiro, Gill, Ankurpreet, Shahryari, Varahram, Tabatabai, Z. Laura, Greene, Kirsten L., Dahiya, Rajvir, Shin, Dong Min, Tanaka, Yuichiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503597/ https://www.ncbi.nlm.nih.gov/pubmed/28388569 http://dx.doi.org/10.18632/oncotarget.16598 |
Ejemplares similares
-
Correction: Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer via caspase-1 activation
por: Chang, Inik, et al.
Publicado: (2018) -
Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma
por: Chang, Inik, et al.
Publicado: (2015) -
CYP1B1 promotes tumorigenesis via altered expression of CDC20 and DAPK1 genes in renal cell carcinoma
por: Mitsui, Yozo, et al.
Publicado: (2015) -
Correction: CYP1B1 promotes tumorigenesis via altered expression of CDC20 and DAPK1 genes in renal cell carcinoma
por: Mitsui, Yozo, et al.
Publicado: (2022) -
Influence of lifestyle choices on risks of CYP1B1 polymorphisms for prostate cancer
por: Kato, Taku, et al.
Publicado: (2018)